Patent classifications
C07D473/18
CYCLIC DINUCLEOTIDES USEFUL FOR THE TREATMENT OF INTER ALIA CANCER
A compound of formula (I)
##STR00001##
or a pharmaceutically acceptable salt and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases and conditions in which modulation of STING (Stimulator of Interferon Genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous syndromes and as vaccine adjuvants
COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.
COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.
ANTIBODY-IMMUNE AGONIST CONJUGATE AND APPLICATIONS THEREOF
The present disclosure relates to a linking unit molecule for targeting molecule-drug conjugate, and the corresponding conjugate, the preparation and use thereof, and in particular relates to an antibody-immune agonist conjugate (AIAC) as a novel type of cancer therapy.
Degradation agent using autophagic mechanism of damaged mitochondria
Provided is a degrader for injured mitochondria based on an autophagy mechanism, the degrader including a compound or a salt thereof, the compound containing a ligand capable of binding to or accumulating in mitochondria and a substituent represented by the following general formula (1): ##STR00001##
where R.sup.1, R.sup.2, and R.sup.3 are identical to or different from each other, and each represent a hydrogen atom or the like.
Degradation agent using autophagic mechanism of damaged mitochondria
Provided is a degrader for injured mitochondria based on an autophagy mechanism, the degrader including a compound or a salt thereof, the compound containing a ligand capable of binding to or accumulating in mitochondria and a substituent represented by the following general formula (1): ##STR00001##
where R.sup.1, R.sup.2, and R.sup.3 are identical to or different from each other, and each represent a hydrogen atom or the like.
ANTI-FIBROTIC COMPOUNDS AND USE THEREOF
The present invention relates to compounds, compositions and methods for treating fibrosis. In particular, compounds that inhibit or downregulate Sirtuin 1 (SIRT1) activity, which are particularly useful in the treatment of Idiopathic Pulmonary Fibrosis (IPF) are provided.
ANTI-FIBROTIC COMPOUNDS AND USE THEREOF
The present invention relates to compounds, compositions and methods for treating fibrosis. In particular, compounds that inhibit or downregulate Sirtuin 1 (SIRT1) activity, which are particularly useful in the treatment of Idiopathic Pulmonary Fibrosis (IPF) are provided.
METHOD OF TREATING MICROBIAL INFECTIONS
The disclosure provides for novel antimicrobial agents, methods of making, and methods of use thereof.
METHOD OF TREATING MICROBIAL INFECTIONS
The disclosure provides for novel antimicrobial agents, methods of making, and methods of use thereof.